Biotech companies in Scotland’s thriving bio-based manufacturing have been invited to apply for up to £1m funding within the Launchpad programme.
Swiss Memo Therapeutics AG will use CHF25m raised in a new Series C financing to complete a Phase II study with Anti-BKV for prevention of virus-induced graft damage.
Researchers led by Wolfgang Enard from LMU Munich have identified a microRNA-based mechanism that drives atherosclerosis by weakening the integrity of blood vessel walls.
Due to the global niche character of pharmaceutical biotechnology, research collaborations and market entries on an international level are essential. Agility and market knowledge are required to maintain an overview in a rapidly evolving environment and to initiate a sustainable internationalisation process.
When businesses receive a proposal from a contract development and manufacturing organisation (CDMO), it’s much like a first date: first impressions matter. The proposal process not only reveals a CDMO’s services but also hints at the potential relationship’s quality. This is gauged mainly through metrics like timing, quality, and price.
AstraZeneca plc has paid French cancer cell therapy developer Cellectis SA US$25m upfront and US$220m in equity in an US$2.2bn R&D deal for up to ten cell and gene therapies.